NASDAQ:ENTA - Enanta Pharmaceuticals Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$99.15 +1.13 (+1.15 %)
(As of 02/22/2019 10:02 AM ET)
Previous Close$98.02
Today's Range$97.56 - $99.65
52-Week Range$64.08 - $127.77
Volume23,049 shs
Average Volume326,752 shs
Market Capitalization$1.93 billion
P/E Ratio28.49
Dividend YieldN/A
Beta1.27
Enanta Pharmaceuticals, Inc., a biotechnology company, focuses on the research and development of small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, non-alcoholic steatohepatitis, primary biliary cholangitis, and hepatitis B virus. Enanta Pharmaceuticals, Inc. has a collaborative development and license agreement with Abbott Laboratories to identify, develop, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir for the treatment of chronic hepatitis C virus. The company was founded in 1995 and is headquartered in Watertown, Massachusetts.

Receive ENTA News and Ratings via Email

Sign-up to receive the latest news and ratings for ENTA and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ENTA
CUSIPN/A
Phone617-607-0800

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$206.63 million
Cash Flow$3.7514 per share
Book Value$21.95 per share

Profitability

Net Income$71.95 million

Miscellaneous

Employees113
Market Cap$1.93 billion
Next Earnings Date5/14/2019 (Estimated)
OptionableOptionable

Enanta Pharmaceuticals (NASDAQ:ENTA) Frequently Asked Questions

What is Enanta Pharmaceuticals' stock symbol?

Enanta Pharmaceuticals trades on the NASDAQ under the ticker symbol "ENTA."

How were Enanta Pharmaceuticals' earnings last quarter?

Enanta Pharmaceuticals Inc (NASDAQ:ENTA) posted its quarterly earnings data on Wednesday, February, 6th. The biotechnology company reported $1.25 EPS for the quarter, missing the Zacks' consensus estimate of $1.46 by $0.21. The biotechnology company earned $69.89 million during the quarter, compared to the consensus estimate of $71.27 million. Enanta Pharmaceuticals had a net margin of 36.19% and a return on equity of 22.78%. The company's revenue for the quarter was up 83.4% compared to the same quarter last year. During the same period in the prior year, the company posted $0.59 earnings per share. View Enanta Pharmaceuticals' Earnings History.

When is Enanta Pharmaceuticals' next earnings date?

Enanta Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Tuesday, May 14th 2019. View Earnings Estimates for Enanta Pharmaceuticals.

What price target have analysts set for ENTA?

6 Wall Street analysts have issued 1 year price targets for Enanta Pharmaceuticals' stock. Their forecasts range from $80.00 to $133.00. On average, they anticipate Enanta Pharmaceuticals' share price to reach $102.60 in the next year. This suggests a possible upside of 4.7% from the stock's current price. View Analyst Price Targets for Enanta Pharmaceuticals.

What is the consensus analysts' recommendation for Enanta Pharmaceuticals?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Enanta Pharmaceuticals in the last year. There are currently 4 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Enanta Pharmaceuticals.

Has Enanta Pharmaceuticals been receiving favorable news coverage?

News coverage about ENTA stock has been trending somewhat positive this week, according to InfoTrie Sentiment. InfoTrie rates the sentiment of press coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Enanta Pharmaceuticals earned a news impact score of 1.0 on InfoTrie's scale. They also gave news coverage about the biotechnology company a news buzz of 2.0 out of 10, indicating that recent press coverage is very unlikely to have an effect on the company's share price in the near future.

Who are some of Enanta Pharmaceuticals' key competitors?

What other stocks do shareholders of Enanta Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Enanta Pharmaceuticals investors own include NVIDIA (NVDA), Intercept Pharmaceuticals (ICPT), Dollar Tree (DLTR), Zoetis (ZTS), Gilead Sciences (GILD), GW Pharmaceuticals PLC- (GWPH), Celgene (CELG), Micron Technology (MU), Viper Energy Partners (VNOM) and ABIOMED (ABMD).

Who are Enanta Pharmaceuticals' key executives?

Enanta Pharmaceuticals' management team includes the folowing people:
  • Dr. Jay R. Luly, Pres, CEO & Director (Age 63)
  • Mr. Paul J. Mellett Jr., Sr. VP of Fin. & Admin. and CFO (Age 64)
  • Dr. Yat Sun Or, Sr. VP of R&D and Chief Scientific Officer (Age 67)
  • Mr. Nathaniel S. Gardiner J.D., Sr. VP, Gen. Counsel & Sec. (Age 65)
  • Dr. Nathalie Adda, Sr. VP & Chief Medical Officer (Age 53)

Who are Enanta Pharmaceuticals' major shareholders?

Enanta Pharmaceuticals' stock is owned by many different of retail and institutional investors. Top institutional investors include BlackRock Inc. (13.24%), First Manhattan Co. (3.50%), Dimensional Fund Advisors LP (3.21%), Krensavage Asset Management LLC (2.76%), Krensavage Asset Management LLC (2.75%) and Acadian Asset Management LLC (1.79%). Company insiders that own Enanta Pharmaceuticals stock include Bruce L A Carter, Jay R Luly, Nathalie Adda, Nathaniel S Gardiner, Paul J Mellett, Tim Ocain and Yat Sun Or. View Institutional Ownership Trends for Enanta Pharmaceuticals.

Which major investors are selling Enanta Pharmaceuticals stock?

ENTA stock was sold by a variety of institutional investors in the last quarter, including Prudential Financial Inc., Acadian Asset Management LLC, Great Point Partners LLC, Mackenzie Financial Corp, First Trust Advisors LP, First Manhattan Co., Barclays PLC and BlackRock Inc.. Company insiders that have sold Enanta Pharmaceuticals company stock in the last year include Bruce L A Carter, Jay R Luly, Nathalie Adda, Nathaniel S Gardiner, Paul J Mellett, Tim Ocain and Yat Sun Or. View Insider Buying and Selling for Enanta Pharmaceuticals.

Which major investors are buying Enanta Pharmaceuticals stock?

ENTA stock was bought by a variety of institutional investors in the last quarter, including Citigroup Inc., Candriam Luxembourg S.C.A., Two Sigma Investments LP, Krensavage Asset Management LLC, Krensavage Asset Management LLC, Millennium Management LLC, KBC Group NV and Dimensional Fund Advisors LP. View Insider Buying and Selling for Enanta Pharmaceuticals.

How do I buy shares of Enanta Pharmaceuticals?

Shares of ENTA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Enanta Pharmaceuticals' stock price today?

One share of ENTA stock can currently be purchased for approximately $98.02.

How big of a company is Enanta Pharmaceuticals?

Enanta Pharmaceuticals has a market capitalization of $1.91 billion and generates $206.63 million in revenue each year. The biotechnology company earns $71.95 million in net income (profit) each year or $3.48 on an earnings per share basis. Enanta Pharmaceuticals employs 113 workers across the globe.

What is Enanta Pharmaceuticals' official website?

The official website for Enanta Pharmaceuticals is http://www.enanta.com.

How can I contact Enanta Pharmaceuticals?

Enanta Pharmaceuticals' mailing address is 500 ARSENAL STREET, WATERTOWN MA, 02472. The biotechnology company can be reached via phone at 617-607-0800 or via email at [email protected]


MarketBeat Community Rating for Enanta Pharmaceuticals (NASDAQ ENTA)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  235 (Vote Outperform)
Underperform Votes:  260 (Vote Underperform)
Total Votes:  495
MarketBeat's community ratings are surveys of what our community members think about Enanta Pharmaceuticals and other stocks. Vote "Outperform" if you believe ENTA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ENTA will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/22/2019 by MarketBeat.com Staff

Featured Article: Cost of Capital Explained

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel